Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Fulcrum Therapeutics, Inc.

FULC ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: HOLD

Last Close

$3.69

▼ -0.54%

Market Cap $281.54M · Vol 255.16K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$281.54M

Micro Cap

Div Yield

N/A

EPS Growth

+35.45%

YoY

RSI (14)

34.38

Momentum

Beta

2.82

vs Market

52W High

$15.50

76.19% below

52W Low

$2.91

26.80% above

Volume

255.16K

Avg 513.26K

P/B

2.16

Price-to-book

ROE

-25.30%

Return on equity

Free Float

96.64%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Fulcrum Therapeutics, Inc. (FULC) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does FULC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.27%

-4.16%

-0.81%

-52.87%

YTD

-67.37%

-61.16%

-11.72%

-85.48%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-74,880,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-25.30%
ROA · ROIC	-23.89% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.16
P/FCF	N/A
EPS Growth	+35.45%
Outstanding Shares	76.30M

Technical Indicators

50-Day SMA	$3.78
200-Day SMA	$6.53
RSI (14)	34.38
Beta	2.82
52-Week High	$15.50
52-Week Low	$2.91

Volume Today	255.16K
Avg Daily Volume (30D)	513.26K
Relative Volume	0.50x
Volatility (10D)	7.78
Volatility (30D)	9.27
Free Float	96.64%

Analyst Consensus

HOLD

Current Price $3.69

Mean Target $7.60

52W Low$2.91 52W High$15.50

Current

Target

$2.91 $15.50

Current Analyst target

+105.96% upside potential · 6 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00DDY1RM7

ISINUS3596161097

CountryUSA

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateOct 27, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +0.24% ONC BeOne Medicines AG +0.31% 068270.KS Celltrion, Inc. -0.11% MEDP Medpace Holdings, Inc. -2.84% ABVX Abivax SA -3.83%

Company Profile

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with rare hematological disorders. The Company's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). It uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of genetically defined diseases. In addition to its product candidates, the Company has developed a discovery approach to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. It also presented preclinical data for FTX-6274, an oral EED inhibitor candidate, demonstrating tumor growth inhibition in castration resistant prostate cancer models.